Abstract Beneficial weight-loss properties of glucagon-like peptide-1 receptor agonists (GLP-1RA) in obese people. with corresponding improvements in cardiometabolic risk factors. are well established. OKV-119 is an investigational drug delivery system that is being developed for the long-term delivery of the GLP-1RA exenatide to feline patients. https://www.remtavares.com/